![](/images/2013/post-sep.jpg)
Opinion/decision on a Paediatric investigation plan (PIP): Sotyktu, Deucravacitinib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Immunology-Rheumatology-Transplantation, PIP…
P/0250/2023 : EMA decision of 14 July 2023 on the granting of a product specific waiver for deucravacitinib (Sotyktu), (EMEA-002350-PIP05-23)
Reference Number: EMA/302856/2023
![](https://pharmaceuticals.einnews.com/tracking/article.gif?aid=727215445§ion=ema.europa.eu&a=hhHoPk0L57ih6wOf&i=4U0lN7dn5cwIad7t)
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.